Wellington Management Group LLP Sells 21,848 Shares of Hims & Hers Health, Inc. (NYSE:HIMS)

Wellington Management Group LLP decreased its stake in Hims & Hers Health, Inc. (NYSE:HIMS - Free Report) by 0.6% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,422,566 shares of the company's stock after selling 21,848 shares during the quarter. Wellington Management Group LLP owned 1.57% of Hims & Hers Health worth $82,758,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also modified their holdings of HIMS. O Shaughnessy Asset Management LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth about $208,000. Summit Securities Group LLC purchased a new stake in Hims & Hers Health in the 4th quarter worth about $38,000. Arrowstreet Capital Limited Partnership lifted its stake in Hims & Hers Health by 192.0% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 6,304,202 shares of the company's stock worth $152,436,000 after acquiring an additional 4,145,305 shares in the last quarter. DnB Asset Management AS lifted its stake in Hims & Hers Health by 116.0% in the 4th quarter. DnB Asset Management AS now owns 138,665 shares of the company's stock worth $3,353,000 after acquiring an additional 74,457 shares in the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in Hims & Hers Health by 26.9% in the 4th quarter. Pictet Asset Management Holding SA now owns 23,129 shares of the company's stock worth $559,000 after acquiring an additional 4,898 shares in the last quarter. Institutional investors and hedge funds own 63.52% of the company's stock.

Hims & Hers Health Trading Down 7.1 %

HIMS traded down $2.09 during midday trading on Thursday, reaching $27.40. The company's stock had a trading volume of 6,098,629 shares, compared to its average volume of 14,961,883. The stock has a market cap of $6.09 billion, a P/E ratio of 62.75 and a beta of 1.65. The company has a fifty day simple moving average of $39.29 and a 200 day simple moving average of $30.23. Hims & Hers Health, Inc. has a twelve month low of $11.20 and a twelve month high of $72.98.

Hims & Hers Health (NYSE:HIMS - Get Free Report) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.09 by $0.02. The firm had revenue of $481.14 million for the quarter, compared to analyst estimates of $494.56 million. Hims & Hers Health had a return on equity of 10.97% and a net margin of 8.19%. Sell-side analysts expect that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Wall Street Analysts Forecast Growth

HIMS has been the subject of several research analyst reports. Citigroup reissued a "sell" rating on shares of Hims & Hers Health in a research note on Wednesday, April 2nd. Leerink Partners raised their price target on Hims & Hers Health from $24.00 to $40.00 and gave the stock a "market perform" rating in a research note on Tuesday, February 25th. Piper Sandler raised their price target on Hims & Hers Health from $24.00 to $35.00 and gave the stock a "neutral" rating in a research note on Tuesday, February 25th. Truist Financial cut their price target on Hims & Hers Health from $39.00 to $33.00 and set a "hold" rating for the company in a research note on Thursday. Finally, Morgan Stanley downgraded Hims & Hers Health from an "overweight" rating to an "equal weight" rating and raised their price target for the stock from $42.00 to $60.00 in a research note on Tuesday, February 18th. Two investment analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus price target of $36.85.

Insider Buying and Selling at Hims & Hers Health

In other news, CFO Oluyemi Okupe sold 11,581 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, April 2nd. The stock was sold at an average price of $29.26, for a total transaction of $338,860.06. Following the sale, the chief financial officer now owns 124,104 shares of the company's stock, valued at approximately $3,631,283.04. This trade represents a 8.54 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Irene Becklund sold 2,203 shares of Hims & Hers Health stock in a transaction that occurred on Thursday, April 3rd. The stock was sold at an average price of $28.78, for a total value of $63,402.34. Following the sale, the insider now directly owns 8,007 shares in the company, valued at $230,441.46. The trade was a 21.58 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 809,806 shares of company stock valued at $30,923,658 in the last 90 days. 17.71% of the stock is currently owned by insiders.

Hims & Hers Health Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.